Get 50% OFF This Summer!
Marksans Pharma
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Marksans Pharma Limited is a public limited company incorporated in the year April 16th, 1982. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.
The Company on 30th March 2015, issued and allotted 240,06,494 equity shares of Rs1/- each to qualified institutional buyers under QIP for cash at Rs54.67 (including premium) per Equity Share. In accordance to terms of issue, the Directors in their meeting held on 7th February, 2015 decided to redeem entire 13,50,000 7% Redeemable Cumulative Preference Shares of face value Rs100/- per share at par out of profits in tranches before due date of redemption i.e 27th March, 2018. Accordingly, on 7th February 2015, the Directors redeemed 1,00,000 preference shares at par.
The Company issued 50,000 Bonds of USD 1,000 each in principal value during the financial year 2015. As on date of report, the Company bought back and extinguished 49,939 Bonds. Of which, only 61 Bonds of USD 1,000 each in principal value (out of total 50,000 Bonds issued) remained outstanding as the same are not traceable
During the year 2017, the Company redeemed 1,50,000 preference shares of Rs100/-each at par. Accordingly, issued, subscribed and paid-up preference share capital reduced from 12,50,000 preference shares of Rs100/- each to 11,00,000 preference shares of Rs100/- each with effect from 31st March 2017.
Marksans Pharma share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Marksans Pharma indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Marksans Pharma is valued compared to its competitors.
Marksans Pharma PE ratio helps investors understand what is the market value of each stock compared to Marksans Pharma 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Marksans Pharma evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Marksans Pharma generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Marksans Pharma in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Marksans Pharma shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Marksans Pharma compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Marksans Pharma over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Marksans Pharma helps investors get an insight into when they can enter or exit the stock. Key components of Marksans Pharma Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Marksans Pharma shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Marksans Pharma ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Marksans Pharma provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Marksans Pharma highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Marksans Pharma .
The balance sheet presents a snapshot of Marksans Pharma ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App